Coya Therapeutics reports preclinical study shows COYA 303 combination cuts inflammation markers in LPS mouse model

PUBT · 1d ago
Coya Therapeutics reports preclinical study shows COYA 303 combination cuts inflammation markers in LPS mouse model
  • Coya Therapeutics disclosed publication of preclinical results for COYA 303, a combination therapy pairing low-dose IL-2 with a GLP-1 agonist.
  • Results were already presented via a peer-reviewed journal publication, not a future conference readout.
  • In an inflammation mouse model, the combination produced broader anti-inflammatory and immune-balancing effects than either agent alone.
  • Findings support further testing in more disease-relevant models, positioning COYA 303 as a potential combo approach for neurodegenerative diseases.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Coya Therapeutics Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20260908230713) on September 08, 2026, and is solely responsible for the information contained therein.